Phaseline

Companies › Prokarium

Prokarium: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZH9
Live attenuated Salmonella enterica serovar Typhi (Ty2 ΔaroC ΔssaV) microbial immunotherap
–Phase 1NMIBC–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06181266ZH9Phase 1NMIBCOncologyAug 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.